{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:49:56Z","timestamp":1782960596325,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.autrev.2012.08.007","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T02:00:49Z","timestamp":1345082449000},"page":"483-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Treatment of ANCA-associated vasculitides (AAV)"],"prefix":"10.1016","volume":"12","author":[{"given":"Julia U.","family":"Holle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2012.08.007_bb0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.007_bb0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprimsulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.qjmed.a030133","article-title":"Response to trimethoprim\/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease","volume":"89","author":"Reinhold-Keller","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2012.08.007_bb0020","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/ard.2010.130203","article-title":"Prospective long-term follow-up of patients with localized Wegener's granulomatosis: does it occur as persistent disease stage?","volume":"69","author":"Holle","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.007_bb0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3899\/jrheum.100518","article-title":"Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database","volume":"38","author":"Pagnoux","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.007_bb0030","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.007_bb0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/qjmed\/90.6.401","article-title":"Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis","volume":"90","author":"Adu","year":"1997","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2012.08.007_bb0040","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.007_bb0045","first-page":"64","article-title":"Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA associated vasculitis\u2014preliminary single center experience","volume":"105","author":"Rihova","year":"2004","journal-title":"Prague Med Rep"},{"key":"10.1016\/j.autrev.2012.08.007_bb0050","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0055","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"de Groot","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2012.08.007_bb0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophopshamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.007_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2012.08.007_bb0075","first-page":"85","article-title":"Long-term efficacy of rituximab in ANCA-associated vasculitis","volume":"70","author":"Specks","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2012.08.007_bb0080","first-page":"57","article-title":"Two-year follow-up results from a randomized controlled trial of RTX versus CyP for ANCA-associated vasculitis: RITUXVAS","volume":"164","author":"Jones","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2012.08.007_bb0085","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/rheumatology\/ker150","article-title":"Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody associated vasculitis","volume":"51","author":"Guerry","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2012.08.007_bb0090","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/rheumatology\/ker002","article-title":"ANCA vasculitis: time for a change in treatment paradigm? Not yet","volume":"50","author":"Ntatsaki","year":"2011","journal-title":"Rheumatology"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2012.08.007_bb0100","first-page":"52","article-title":"Plasma exchange for severe renal vasculitis: long-term follow-up of the MEPEX trial","volume":"164","author":"Casian","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2012.08.007_bb0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0110","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine of methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2012.08.007_bb0120","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs. azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2012.08.007_bb0125","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.2130","article-title":"A CD8+ T cell transcription signature predicts prognosis in autoimmune disease","volume":"16","author":"McKinney","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.27763","article-title":"Improved outcome of 445 Wegener's granulomatosis patients in a German vasculitis center over four decades","volume":"63","author":"Holle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.007_bb0135","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.007_bb0140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2012.08.007_bb0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2012.08.007_bb0150","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.007_bb0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Retrospective study of rituximab (RTX) in refractory granulomatosis with polyangiitis (Wegener's, GPA): comparison of treatment response in vasculitis versus granulomatous manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.007_bb0160","first-page":"243","article-title":"Churg\u2013Strauss syndrome: evolving concepts","volume":"9","author":"Pagnoux","year":"2010","journal-title":"Discov Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0165","article-title":"A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","author":"Moosig","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.007_bb0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.md.0000180793.80212.17","article-title":"Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg\u2013Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients","volume":"84","author":"Bourgarit","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2012.08.007_bb0175","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg\u2013Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6 Suppl. 36","key":"10.1016\/j.autrev.2012.08.007_bb0180","first-page":"S52","article-title":"Churg Strauss syndrome\u2014successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.007_bb0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognostic factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.007_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2332\/allergolint.R-07-142","article-title":"Treatment for Churg\u2013Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy","volume":"56","author":"Taniguchi","year":"2007","journal-title":"Allergol Int"},{"key":"10.1016\/j.autrev.2012.08.007_bb0195","first-page":"S35","article-title":"A phase II study of interferon-alpha for the treatment of refractory Churg\u2013Strauss syndrome","volume":"26","author":"Metzler","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.007_bb0200","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1078\/0171-2985-00197","article-title":"Treatment of refractory Churg\u2013Strauss-syndrome (CSS) by TNF-alpha blockade","volume":"206","author":"Arbach","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2012.08.007_bb0205","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","article-title":"Rituximab is effective in the treatment of refractory Churg\u2013Strauss syndrome and is associated with diminished T-cell interleukin-5 production","volume":"47","author":"Pepper","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.08.007_bb0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2012.08.007_bb0215","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg\u2013Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2012.08.007_bb0220","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T12:34:23Z","timestamp":1542803663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997212001711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1568997212001711"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2012.08.007","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of ANCA-associated vasculitides (AAV)","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2012.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}